Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

3.765 -0.185 (-4.68%)
Delayed Quote Updated: 3:37 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MannKind Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
News headline image
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces $50 Million Private Placement
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
From MannKind
Via GlobeNewswire
News headline image
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
From MannKind
Via GlobeNewswire
News headline image
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
From MannKind
Via GlobeNewswire
News headline image
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
From MannKind
Via GlobeNewswire
News headline image
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Settlement of Convertible Senior Notes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D 
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
From MannKind
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
MannKind Provides Business Updates and 2026 Growth Drivers
From MannKind
Via GlobeNewswire
News headline image
MannKind Shares FUROSCIX® Business Updates
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at the Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.